Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Jayastu SenapatiWarren C FiskusNaval G DaverNathaniel R WilsonFarhad RavandiGuillermo Garcia ManeroTapan Mahendra KadiaCourtney D D DiNardoElias J JabbourJan A BurgerNicholas James ShortYesid AlvaradoNitin JainLucia MasarovaGhayas C IssaWei QiaoJoseph D KhourySherry PierceDarla MillerKoiji SasakiMarina Y KonoplevaKapil N BhallaGautam BorthakurNaveen PemmarajuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In a heavily pre-treated patient cohort with R/R MDS and AML, PLX51107+ azacitidine was well-tolerated and resulted in modest clinical benefit.